ESR1 and breast carcinoma: Subtyping of breast cancer by complementing IHC tests with genomic tests for determining the ER (ESR1), PR (PGR), and HER2 (ERBB2) status could provide accurate classification results and further treatment of the patients can be based on the subtyping.